Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

By Hiscox Stephen   Morgan Liam   Barrow Denise   Dutkowski Carol   Wakeling Alan   Nicholson Robert  

Clinical and Experimental Metastasis, Vol. 21, Iss. 3, 2004-05 ,pp. : 201-212

Springer Publishing Company

Access to resources Recommend Favorite

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

By Ahnström Marie  

Breast Cancer Research and Treatment, Vol. 91, Iss. 2, 2005-05 ,pp. : 145-151

Springer Publishing Company

Access to resources Recommend Favorite

Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer

By Lauro Luigi   Vici Patrizia   Medico Pietro   Laudadio Lucio   Tomao Silverio   Giannarelli Diana   Pizzuti Laura   Sergi Domenico   Barba Maddalena   Maugeri-Saccà Marcello  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 119-123

Springer Publishing Company

Access to resources Recommend Favorite

Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 95-102

Spandidos Publications

Access to resources Recommend Favorite

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

By Sonne-Hansen Katrine  

Breast Cancer Research and Treatment, Vol. 121, Iss. 3, 2010-06 ,pp. : 601-613

Springer Publishing Company

Access to resources Recommend Favorite